

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 523.1006US		SERIAL NO.: 10/560,889							
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Ronald AUNG-DIN									
				FILING DATE: May 15, 2006		GROUP: 1627							
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	FA	5	7	4	4	4	8	2	04/1998	Cohen et al			
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
	FB												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	FC	Aung-Din, Ronald, Transdermal Sumatriptan: A Novel Dosage Form Efficacious in the Treatment of Acute Migraine, Headache: The Journal of Head and Face Pain, vol. 45, No. 5, May 2002											
	FD	Aung-Din, Ronald, Transdermal Sumatriptan in Clinical Practice: The Experience of 42 Patients with Acute Migraine in an Outpatient Setting, Headache: The Journal of Head and Face Pain, vol. 43, No. 5, May 2003											
	FE	Aung-Din, Ronald and Kinnard, Fred, Topical Tizanidine (Zanaflex) Gel Effective in Migraine and Tension-Type Headache, Headache: The Journal of Head and Face Pain, vol. 44, No. 5, May 2004											
	FF	Norton, Patrice G.W., Transdermal Sumatriptan May Relieve Migraines, Internal Medicine News, vol. 36, Issue 19, Page 14, October 1, 2003											
	FG	Copy of International Search Report dated November 5, 2002 issued in corresponding International Patent Application No. PCT/US02/17585											
	FH	Copy European Search Report dated October 3, 2006 issued in corresponding European Patent Application No. 02 739 657.1-2123											
	FI	Copy of International Search Report dated June 6, 2005 issued in corresponding International Patent Application No. PCT/US04/19816											
	FJ	Aung-Din, R. et al, "Transdermal sumatriptan: effectiveness and convenience in migraineurs, Blackwell Science Ltd. Cephalalgia, 2001, 21, 405-432											
	FK	Bartsch, T. and Goadsby P.J., "Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater", Brain, Vol. 126, No. 8, 1801-1813, August 2003											
EXAMINER									DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.M./

Sheet 2 of 2

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 523.1006US		SERIAL NO.: 10/560,889	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Ronald AUNG-DIN			
				FILING DATE: May 15, 2006		GROUP: 1627	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	GA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	GB						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	GC	Bogduk, Nikolai, MD, PhD, "Cervicogenic Headache: Anatomic Basis and Pathophysiologic Mechanisms", Current Pain and Headache Reports 2001, 5:382-386					
	GD	Aung-Din, Ronald, MD, "Topical Delivery: Topical Regional Neuro-Affective (TRNA) Therapy: Novel Ground-Breaking Triptan Drug Delivery for Treating Migranes", Drug Delivery Technology, September 2009, Vol. 9, No.8					
	GE	Pierce, Mark et al, "Zelrix: a novel transdermal formulation of sumatriptan" Headache, Vol. 49, June 2009, pp. 817-825					
	GF	Patel, SR et al, "Controlled non-invasive transdermal iontophoretic delivery of zolmitriptan hydrochloride in vitro and in vivo" Eur. J. Pharm. And Biopharm, Vol. 72, February 2009, pp. 304-309					
	GG	Garg, T et al, "Elastic liposomal formulation for sustained delivery of antimigraine drug: In vitro characterization and biological evaluation" Drug Dev. Ind. Pharm., Vol. 34, October 2008, pp. 1100-1110					
	GH	Copy of Office Action dated August 1, 2007 issued in corresponding US Patent Application No. 10/163,234					
	GI	Copy of Applicant's Response to Office Action dated January 19, 2007 issued in corresponding U.S. Patent Application 10/163,234					
	GJ	Copy of Office Action dated September 21, 2006 issued in corresponding US Patent Application No. 10/163,234					
	GK	Copy of Applicant's Response to Office Action dated March 15, 2006 issued in corresponding U.S. Patent Application 10/163,234					
	GL	Copy of Office Action dated November 17, 2005 issued in corresponding US Patent Application No. 10/163,234					
	GM	Copy of Applicant's Response to Office Action dated August 18, 2005 issued in corresponding U.S. Patent Application 10/163,234					
	GN	Copy of Office Action dated April 18, 2005 issued in corresponding US Patent Application No. 10/163,234					
	GO	Copy of Applicant's Response to Office Action dated January 6, 2010 issued in corresponding US Patent Application 11/999,093					
	GP	Copy of Office Action dated October 27, 2009 issued in corresponding US Patent Application 11/999,093					
	GQ	Copy of Applicant's Response to Office action dated May 19, 2009 issued in corresponding US Patent Application 11/999,093					
	GR	Copy of Office Action dated March 19, 2009 issued in corresponding US Patent Application 11/999,093					
	GS	Copy of Applicant's d Response to Office Action dated December 12, 2008 issued in corresponding US Patent Application 11/999,093					
	GT	Copy of Applicant's Response to Office Action dated October 21, 2008 issued in corresponding US Patent Application 11/999,093					
	GU	Copy of Office Action dated June 23, 2008 issued in corresponding US Patent Application 11/999,093					
EXAMINER /Kara McMillian/				DATE CONSIDERED 06/04/2010			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							